Harmony Biosciences Holdings, Inc. HRMY

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are cultivating a differentiated neuroscience company, rooted in innovation and driven by a commitment to addressing the unmet needs of patients living with neurological diseases. To date, we have focused on rare neurological diseases with a growing portfolio now spanning sleep/wake, rare epilepsy, and neurobehavioral and we are harnessing scientific insights and pioneering approaches to advance meaningful treatments that help patients thrive.

In July 2017, we entered into a License Agreement (as amended, the "2017 LCA") with Bioprojet Société Civile de Recherche ("Bioprojet") whereby we acquired the exclusive right to commercialize the pharmaceutical compound pitolisant. Our lead product, WAKIX® (pitolisant) ("WAKIX"), is a first-in-class therapy with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Since its initial FDA approval in 2019 for excessive daytime sleepiness ("EDS") in adult patients with narcolepsy and subsequent approvals for cataplexy in adult patients in 2020, EDS in pediatric patients six years and older in 2024 and cataplexy in pediatric patients six years and older in 2026, WAKIX has continued to reshape the treatment landscape for narcolepsy and remains the only FDA-approved treatment for narcolepsy that is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration ("DEA").

Last close 36.13 2026-10-23
Market cap $2.10B 2026-06-30 share count
52-week range 25.90 - 43.49

Valuation FY2025 figures against the last close

P/S2.4x
P/E13.3x
P/FCF6.0x
EV/EBITDA7.2x
Dividend yield—
Diluted EPS2.71

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $868.5M$714.7M$582.0M$437.9M$305.4M$159.7M$6.0M—
Cost of revenue $198.3M$156.8M$121.2M$83.5M$55.5M$27.7M$1.6M—
Gross profit $670.1M$557.9M$460.8M$354.4M$249.9M$132.0M$4.4M—
R&D $189.6M$145.8M$76.1M$70.9M$30.4M$19.4M$69.6M—
SG&A $152.5M$110.4M$95.3M$84.0M$63.9M$39.7M$36.4M—
Total operating expenses $461.6M$367.1M$268.8M$234.2M$162.4M$115.0M$150.3M—
Operating income $208.5M$190.8M$192.0M$120.2M$87.5M$17.0M-$145.9M—
Interest expense $14.6M$17.5M$23.8M$18.8M$24.2M———
Pre-tax income $215.1M$191.8M$173.4M$104.7M$37.4M-$36.9M-$152.0M—
Income tax $56.4M$46.3M$44.5M$76.8M$2.8M———
Net income $158.7M$145.5M$128.9M$181.5M$34.6M-$36.9M-$152.0M—
EPS, basic 2.762.562.173.070.60-2.48-24.07—
EPS, diluted 2.712.512.132.970.58-2.48-24.07—
Shares, diluted (wtd. avg.) 58.5M57.9M60.4M61.1M59.2M25.8M7.8M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $752.5M$453.0M$311.9M$244.5M$235.1M$229.4M$25.2M$84.0M
Short-term investments $22.8M$14.2M$41.8M$79.3M————
Receivables $96.8M$83.0M$74.1M$54.7M$34.8M$22.2M$4.3M—
Inventory $5.4M$7.2M$5.4M$4.3M$4.4M$3.8M$1.1M—
Total current assets $907.0M$579.3M$451.1M$400.3M$284.4M$262.9M$31.5M—
Property, plant and equipment —$1.3M$371.0K$573.0K$820.0K$938.0K$1.3M—
Other intangibles $89.4M$113.3M$137.1M$161.0M$143.9M$162.3M$72.2M—
Total assets $1.27B$999.2M$811.4M$673.9M$433.4M$427.1M$106.7M—
Accounts payable $17.7M$13.7M$17.7M$3.8M$1.0M$2.6M$6.4M—
Short-term debt $20.0M$16.2M$15.0M$2.0M$2.0M———
Total current liabilities $252.1M$175.1M$163.8M$78.9M$53.8M$134.5M$19.9M—
Long-term debt $143.7M$163.0M$178.6M$189.6M$190.0M$194.2M$97.9M—
Total liabilities $401.4M$340.0M$344.5M$271.0M$246.9M$329.9M$118.3M—
Retained earnings $160.9M$2.2M-$143.3M-$272.1M-$453.6M-$488.2M-$422.9M—
Total equity $870.2M$659.2M$467.0M$402.8M$186.5M$97.2M-$422.9M-$242.7M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $348.2M$219.8M$219.4M$144.5M$98.6M-$3.0M-$75.4M—
Depreciation and amortisation —$267.0K$514.0K$419.0K$416.0K$394.0K$395.0K—
Stock-based compensation $44.9M$42.6M$31.7M$26.2M$15.7M$4.7M$9.9M—
Capital expenditure $310.0K$1.2M$312.0K$172.0K$298.0K$2.0K$149.0K—
Investing cash flow -$39.6M-$67.5M-$46.4M-$141.8M-$100.3M-$2.0M-$127.1M—
Financing cash flow -$9.0M-$11.0M-$105.6M$6.8M$7.4M$209.2M$143.8M—
Buybacks ——$100.0M——$167.0K——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-018859.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B Revenue, FY2019: 6M Gross profit, FY2019: 4.4M Net income, FY2019: -152M Revenue, FY2020: 159.7M Gross profit, FY2020: 132M Net income, FY2020: -36.9M Revenue, FY2021: 305.4M Gross profit, FY2021: 249.9M Net income, FY2021: 34.6M Revenue, FY2022: 437.9M Gross profit, FY2022: 354.4M Net income, FY2022: 181.5M Revenue, FY2023: 582M Gross profit, FY2023: 460.8M Net income, FY2023: 128.9M Revenue, FY2024: 714.7M Gross profit, FY2024: 557.9M Net income, FY2024: 145.5M Revenue, FY2025: 868.5M Gross profit, FY2025: 670.1M Net income, FY2025: 158.7M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $6.0M $159.7M $305.4M $437.9M $582.0M $714.7M $868.5M
Gross profit — $4.4M $132.0M $249.9M $354.4M $460.8M $557.9M $670.1M
Net income — -$152.0M -$36.9M $34.6M $181.5M $128.9M $145.5M $158.7M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Regulation FD disclosure Item 7.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Regulation FD disclosure Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%